Company Announcements

CHICAGO--(BUSINESS WIRE)--Apr. 18, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise and strategic advice to Tempus on matters related to research, product development, and clinical utility across the various aspects of the company’s AI-enabled platform.

“Since the beginning, our belief has been that clinical need and strong science must drive our work,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate physician leaders to support and guide our scientific and medical direction across the company, and we look forward to expanding the board as we continue to grow and evolve.”

This group features the following advisors:

• David Carbone, MD, PhD: Dr. Carbone is a Professor of Medical Oncology, Director of the James Thoracic Oncology Center at the Ohio State University Medical Center.
• Babar Bashir, MD, MS, FACP: Dr. Bashir is an Associate Professor with a primary appointment in the Department of Medical Oncology, Division of Solid Tumors, and a secondary appointment in the Department of Pharmacology, Physiology, & Cancer Biology at Thomas Jefferson University.
• Amy Cummings, MD, PhD: Dr. Cummings is an assistant professor in the division of hematology/oncology at the University of California Los Angeles.
• Tapan M. Kadia, MD: Dr. Kadia is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center and serves as Co-leader of the sections of AML and developmental therapeutics.
• Marc R. Matrana, MD: Dr. Matrana is an Endowed Professor and System Director of Precision Medicine at Ochsner MD Anderson Cancer Center. He also holds a Full Professorship at the University of Queensland. His medical oncology practice focuses on cancers of the genitourinary tract.
• Robert McWilliams, MD, MSc, MSHA: Dr. McWilliams is a consultant and Professor of Oncology at Mayo Clinic as well as Deputy Director of the Cancer Practice at the Mayo Clinic Comprehensive Cancer Center.
• Tara Mitchell, MD: Dr. Mitchell is the Section Chief, Melanoma and Sarcoma, Hematology Oncology and Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania.
• Nicholas Mitsiades, MD, PhD: Dr. Mitsiades is the Albert Holmes Rowe Chair of Genetics Ill Professor of Medicine and Associate Director for Translational Research at the UC Davis Comprehensive Cancer Center.
• Ben Park, MD, PhD: Dr. Park is the Director of the Vanderbilt-Ingram Cancer Center. Dr. Park is also a Professor of Medicine in the Department of Medicine's Division of Hematology and Oncology.
• B. J. Rimel, MD: Dr. Rimel is an Associate Professor of Obstetrics & Gynecology at Cedars-Sinai and the Medical Director of Cancer Clinical Trials Office at Cedars-Sinai Cancer.
• Mothaffar Rimawi, MD: Dr. Rimawi is the Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center.
• Assuntina G. Sacco, MD: Dr. Sacco is a Professor of Internal Medicine, Division of Hematology-Oncology, and Co-Director of the Hanna and Mark Gleiberman Head and Neck Center of Excellence at UC San Diego Health Moores Cancer Center.
• Alexander Spira, MD, PhD: Dr. Spira is the Co-Director of the Virginia Cancer Specialists Research Institute, CEO and Director of NEXT Oncology Virginia, Chair of the Research Advisory Board of USOncology, and Clinical Assistant Professor at Johns Hopkins.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of biological modeling solutions in therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250418999150/en/

Erin Carron
media@tempus.com

Source: Tempus AI, Inc.